Biogen Inc. develops and commercializes biopharmaceutical therapies focused on neurodegenerative diseases, rare diseases and adjacent specialty areas. Company news commonly covers Alzheimer’s disease therapy LEQEMBI with Eisai, spinal muscular atrophy treatment SPINRAZA, Friedreich’s ataxia therapy SKYCLARYS, postpartum depression therapy ZURZUVAE, ALS therapy QALSODY, multiple sclerosis products and CD20 collaboration revenue tied to Roche-partnered medicines.
Recurring updates include FDA review activity, supplemental biologics license applications, global regulatory status, clinical development programs, collaboration and licensing economics, asset-rights transactions and product demand trends. Biogen news also includes financial results, acquired in-process research and development expense, governance changes and corporate-status disclosures typical of a Nasdaq-listed biotechnology issuer.
Biogen (BIIB) and Eisai announced Clarity AD substudy findings showing that lecanemab slowed clinical decline versus placebo in people with early Alzheimer's disease.
At Month 18, decline on the CDR-SB scale, a measure of overall clinical status, was 26% lower versus placebo across 400 participants tested for α-synuclein pathology, compared with 27% lower in the full trial population. In the exploratory analysis of 82 α-synuclein-positive participants, decline on the same scale was 41% lower versus placebo. That subgroup also showed 43% less decline versus placebo on each of two scales that assess cognition and daily function, respectively.
Among participants with usable baseline amyloid scans, mean amyloid burden was 86 Centiloids in the α-synuclein-positive group versus 67 in the negative group. A positive test was also associated with faster clinical decline over 18 months.
Biogen (BIIB) and Eisai presented three-year real-world LEQEMBI findings from the ongoing LEADER study in early Alzheimer’s disease.
The retrospective study covered 560 patients at 13 U.S. sites. A prespecified comparison found a 76% lower rate of progression to moderate or severe Alzheimer’s dementia through 36 months versus a matched external cohort. After approximately 18 months of treatment on average, 81.1% of 546 assessable patients were stable or improved. Among 43 patients with paired brain scans, 77% became amyloid-negative at a median follow-up of 18.1 months.
A separate exploratory analysis of approximately 5,000 patients found a lower rate of amyloid-related imaging abnormalities (ARIA) than in Clarity AD (12.4% vs. 21.5%). In LEADER, no ARIA events were reported during under-the-skin maintenance treatment among the 64 patients who switched to it.
Biogen (BIIB) reported that investigational diranersen slowed clinical decline by 38% at two years in the Phase 2 CELIA Alzheimer’s study. The 60 mg twice-yearly regimen produced a 1.09-point treatment difference on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), versus participants originally assigned placebo. Slowing on this measure increased from 26% at Week 76 to 38% at Week 96; treatment effects increased on five of six clinical measures.
The two-year analyses came from an open-label extension, where treatment assignments were known. Original placebo participants had received no diranersen doses or one dose by Week 96. No new safety signals were observed through two years. Additional 18-month findings showed reductions in tau biomarkers. Biogen said the findings support continued development and further evaluation in a Phase 3 trial to confirm efficacy and safety.
Biogen (Nasdaq: BIIB) and Eisai presented five-year lecanemab results from the Clarity AD long-term extension in early Alzheimer’s disease. Among 351 patients receiving continuous treatment for five years, the difference in change on CDR-SB, a measure of cognition and daily function, was −2.05 points versus ADNI and −2.54 points versus BioFINDER external comparison data. Relative risk of progression to the next disease stage was reduced by 36% versus ADNI; 61.9% of treated patients progressed, compared with 77.5% in ADNI.
Among patients with low tau, indicating earlier disease, 66% had no CDR-SB decline and 62% improved at five years. No new safety findings emerged. Brain swelling or fluid accumulation occurred in 13.5% during the first 12 months, falling to 0.6% in the fifth 12-month interval. The original randomized, placebo-controlled study lasted 18 months; the five-year comparisons used external datasets.
Biogen (BIIB) and UCB reported additional Phase 3 lupus analyses associating dapirolizumab pegol with higher treatment response rates than placebo. In a post-hoc analysis of PHOENYCS GO, the novel Treatment Response Measure for Systemic Lupus Erythematosus assessed improvement across active organ domains. Through Week 48, response rates with dapirolizumab pegol plus standard care versus placebo plus standard care were 61.2% versus 43.2% for improvement in at least half of active domains and 52.5% versus 36.8% for all active domains.
Separate post-hoc analyses found higher sustained low disease activity and remission rates across Weeks 40, 44 and 48. The trial previously met its primary disease-response endpoint at Week 48: 50% versus 35%, p=0.011. Treatment-emergent adverse events were more common with treatment, but serious events were less frequent. The novel response measure requires further validation.
Stoke Therapeutics (Nasdaq: STOK) announced that its executives will present at investor conferences beginning November 10, 2026. Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Guggenheim Healthcare Innovation Conference in Boston at 1:00 p.m. ET and at the Jefferies London Global Healthcare Conference on November 17 at 4:00 p.m. GMT. Live webcasts and archived replays will be available on Stoke’s investor website.
Stoke Therapeutics (STOK) reported a third-quarter net loss of $73.6 million and updated progress on its clinical development programs. Revenue rose to $11.3 million from $10.6 million a year earlier, while the loss widened from $38.3 million. Cash, cash equivalents and marketable securities totaled $358.8 million at September 30, 2026; Stoke expects funding into early 2028.
In the Phase 3 EMPEROR study of investigational Dravet syndrome treatment zorevunersen, approximately 110 patients reached Week 28 and approximately 20 reached Week 52, with no treatment discontinuations. Stoke anticipates data in Q3 2027 and plans a U.S. New Drug Application in H2 2027. Following FDA discussions, cognition and behavior will be evaluated using four Vineland-3 assessment subdomains. Third-cohort dosing is underway in the Phase 1 STK-002 study for autosomal dominant optic atrophy, with initial safety and efficacy data anticipated in H1 2027.
Biogen (BIIB) will present Alzheimer’s disease portfolio data at the CTAD conference in Boston on November 16–19, 2026. A diranersen symposium will feature 96-week extension efficacy and safety data from the Phase 2 CELIA study, alongside additional 76-week biomarker and clinical analyses.
Lecanemab presentations will include initial five-year Clarity AD open-label extension findings on clinical outcomes, disease progression and safety. A separate session will cover three-year LEADER real-world evidence, including maintenance treatment and experience with at-home subcutaneous administration. The announcement schedules these presentations but does not disclose their results.
Stoke Therapeutics (Nasdaq: STOK) will host a webcast and conference call on October 29, 2026, to discuss third-quarter business and financial updates. Management will speak at 4:30 p.m. ET. The webcast will be available through the Investors & News section of Stoke’s website, with an archived replay available for at least 90 days following the event.
Biogen (BIIB) will present new 76-week EMPAVELI kidney-disease data at American Society of Nephrology Kidney Week, October 22–25, 2026.
Biogen reports sustained reductions in protein in urine and continued stabilization of estimated kidney filtration, with a consistent long-term safety profile, in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). Presentations include a pediatric subgroup analysis. The FDA recently expanded EMPAVELI’s indication to include reducing kidney-function loss in adults and adolescents aged 12 years and older with these diseases.
Investigational felzartamab is being studied in three Phase 3 trials covering antibody-mediated rejection in adult kidney transplant recipients, IgA nephropathy and primary membranous nephropathy, plus a Phase 2 microvascular inflammation trial. Biogen expects TRANSCEND rejection-study data in H1 2027.